Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.36 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194762 | 0.86 | APP (0.45) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1194139 | 0.86 | MAOB (0.53) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1194605 | 0.86 | MAOB (0.53) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1194689 | 0.86 | MAOB (0.53) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1194529 | 0.86 | APP (0.45) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1194486 | 0.86 | MAOB (0.53) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1195206 | 0.86 | MAOA (0.53) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1194741 | 0.83 | FBP1 (0.48) | APPFBP1PTGS2PTGS1NPC1 | |
| SCHEMBL1195115 | 0.83 | PTGS2 (0.57) | APPFBP1PTGS2PTGS1MAPT | |
| SCHEMBL3237534 | 0.83 | PTGS2 (0.57) | APPFBP1PTGS2PTGS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056953-B2 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1173160-B1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-11-18 | — | — | US | disclosed |
| US-6787667-B2 | POLYSULFONSTYRENE POLYMER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-09-07 | — | — | US | disclosed |
| US-6762207-B1 | TARGETING RECEPTOR TYROSINE KINASES; SELECTIVE TUMOR CELL APOPTOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-13 | — | — | US | disclosed |
| US-20030216535-A1 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-11-20 | — | — | US | disclosed |
| EP-1173160-A4 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1173160-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000059495-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216535-A1 | (E)-styryl sulfone anticancer agents | KRAS, CCNE1, MCL1 | APP 4681/4885FBP1 2514/4885PTGS2 3068/4885 |
| US-20040229959-A1 | (E)-styryl sulfone anticancer agents | SULT1E1, CCNE1, RPS3A | APP 4705/4885FBP1 2520/4885PTGS2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.